| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.jfllifesciences.com | |
| Market Cap | 43.22 Cr. | |
| Enterprise Value(EV) | 50.21 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 2.55 | Trailing Twelve Months Ending 2023-03 |
| Price-Earning Ratio (PE) | 15.38 | Trailing Twelve Months Ending 2023-03 |
| Industry PE | 41.01 | Trailing Twelve Months Ending 2023-03 |
| Book Value / Share | 29.34 | Trailing Twelve Months Ending 2023-03 |
| Price to Book Value | 1.34 | Calculated using Price: 39.30 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 1.10 Cr. | 10,998,441 Shares |
| FaceValue | 10 | |
| About JFL Life Sciences Ltd. | ||
| JFL Life Sciences manufactures a wide range of pharmaceutical formulations. The company’s major products types are Dry powder injections; Tablets & Capsules (B-Lactam) solid oral dosage form; Tablet and capsules (General); and Oral Rehydration Solutions (ORS). | ||
| 1 Day |
|
-1.63% |
| 1 Week |
|
-10.07% |
| 1 Month |
|
-3.08% |
| 3 Month |
|
-15.94% |
| 6 Month |
|
-17.70% |
| 1 Year |
|
-3.91% |
| 2 Year |
|
|
| 5 Year |
|
|
| 10 Year |
|
| 5 years | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 6.03 | 6.94 | 8.85 | 30.94 | 12.9 | |
| Return on Capital Employed (%) | 8.71 | 11.8 | 10.32 | 23.14 | 15.44 | |
| Return on Assets (%) | 1.87 | 1.78 | 2.03 | 7.27 | 5.77 |
| Particulars | 6 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 5 | 5 | 7 | 11 | 32 | 34 | |
| Non Curr. Liab. | 3 | 1 | 8 | 9 | 2 | 1 | |
| Curr. Liab. | 8 | 18 | 14 | 28 | 15 | 18 | |
| Minority Int. | |||||||
| Equity & Liab. | 16 | 24 | 29 | 48 | 49 | 53 | |
| Non Curr. Assets | 3 | 6 | 9 | 9 | 8 | 8 | |
| Curr. Assets | 14 | 18 | 20 | 39 | 41 | 46 | |
| Misc. Exp. not W/O | |||||||
| Total Assets | 16 | 24 | 29 | 48 | 49 | 53 |
| Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Net Sales | 32 | 30 | 33 | 34 | 43 | |
| Other Income | 0 | 0 | 1 | 2 | ||
| Total Income | 32 | 30 | 33 | 34 | 44 | |
| Total Expenditure | -30 | -28 | -31 | -28 | -39 | |
| PBIDT | 1 | 2 | 2 | 6 | 6 | |
| Interest | -1 | -1 | -1 | -2 | -1 | |
| Depreciation | 0 | 0 | 0 | 0 | 0 | |
| Taxation | 0 | 0 | 0 | -1 | -1 | |
| Exceptional Items | ||||||
| PAT | 0 | 0 | 1 | 3 | 3 | |
| Adjusted EPS | 1 | 1 | 1 | 4 | 3 |
| Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | -3 | 3 | -6 | 2 | -9 | |
| Cash Fr. Inv. | -1 | -3 | -2 | -1 | 1 | |
| Cash Fr. Finan. | 4 | 0 | 7 | -1 | 8 | |
| Net Change | 0 | 0 | 0 | 0 | ||
| Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 |
|
Thu, 11 Apr 2024
Certificate under SEBI (Depositories and Participants) Regulations, 2018 Jfl Life Sciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |
|
Thu, 11 Apr 2024
Updates Jfl Life Sciences Limited has informed the Exchange regarding 'Non-Applicability of Corporate Governance Provisions to the Company.'. |
|
Thu, 11 Apr 2024
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter Jfl Life Sciences Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q4 FY 2023-24 |
| Thu, 18 Apr 2024 |
High Delivery Percentage
|
Close Within 52 Week Low Zone
|
Making Lower Lows for 2 Days
|
High Decrease in 1 Month
|
High Decrease in 3 Months
|
